Summary.-The effect of renal failure on melphalan pharmacology and toxicity has been poorly understood. Such information is of interest because melphalan is the most commonly used anticancer drug in the treatment of multiple myeloma, which is frequently associated with renal failure. We have studied the disposition and marrow toxicity of parenteral melphalan in dogs before and after induction of renal failure with subtotal nephrectomy. The surgical procedure decreased the creatinine clearance by an average of 62% (P=0-001). The lowest neutrophil counts following i.v. melphalan (1 mg/kg) averaged 4.9 x 103/mm3 pre-nephrectomy and 0-9 x 103/mm3 post -nephrectomy, respectively (P = 0.002). The mean lowest recorded platelet counts after melphalan (1 mg/kg) were 115 x 103/mm3 in the pre-nephrectomized dogs, and 9-7 x 103/mm3 in those who had been nephrectomized (P=0.002). Following nephrectomy, i.v. melphalan's terminal-phase plasma half-life and renal clearance were both raised (P=0.02) to 75%O over pre-nephrectomy values. These studies show that i.v. melphalan-induced myelosuppression is markedly increased and its plasma elimination and renal clearance significantly decreased in the presence of renal dysfunction in dogs. These data suggest that parenteral melphalan's starting dose be decreased by at least 50%o when used in myeloma patients with renal failure.
by at least 50%o when used in myeloma patients with renal failure.
MELPHALAN continues to be one of the most important anticancer drugs in the treatment of multiple myeloma (Speed et al., 1964; Alexanian et al., 1968; Bergsagel et al., 1979) . As many as one third of all myeloma patients will have severely reduced renal function as a result of renal tubular damage from paraprotein deposition and/or the toxic effects of hypercalcaemia (Kayle & Bayrd, 1976) . Although the alkylating agent melphalan is commonly used in myeloma patients with renal failure, it is not known whether renal dysfunction alters its pharmacokinetics or marrow toxicity. Speed et al. (1964) suggested that the rate of melphalan urinary excretion might be decreased in the presence of renal failure. We have studied the disposition and marrow toxicity of melphalan in dogs before and after surgically induced renal failure. The results of these studies suggest that severe renal dysfunction can slow the plasma and renal clearance of melphalan and markedly increase neutropenia and thrombocytopenia.
MATERIALS ANI) METHODS
Dogs.-Eight male mongrel dogs, weighing 17-23 kg, which had been previously quarantined for 2-4 weeks in the vivarium, were used. The dogs were without evidence of infection and were not given other drugs during the entire duration of the melphalan studies. Baseline BUN, serum creatinine, and 24h urinary creatinine clearance were measured in each of the animals, and were remeasured after the surgical induction of renal dysfunction.
An indwelling 16-gauge catheter was inserted into a superficial leg vein. Melphalan
(1 mg/kg body weight) wAas injected i.v. over about 1 min, followed by 10 ml normal saline. The catheter was thoroughly flushed several times with blood after melphalan injection and blood samples were taken through this catheter.
Surgical procedures.-Four to six weeks after the first dose of melphalan, azotemia was produced by unilateral total nephrectomy and contralateral partial nephrectomy. Gierke et al., 1978 . The right kidney was removed through a midabdominal incision. Branches of the contralateral renal artery were ligated and the extent of necrosis was determined by observing ischemia on the surface of the kidney until about one quarter of the remaining kidney remained viable. If the arterial branching at the renal pelvis was not sufficiently extensive to accomplish this, part of the kidney was ligated with number 0 chromic gut after the capsule was lifted from the ligated segment of renal parenchyma. The capsule was sewn over the ligated portion of the kidney parenchyma to control bleeding. The experimental protocol previously described (i.e., melphalan, 1 mg/kg i.v.) was repeated when serum electrolytes, creatinine and blood urea nitrogen (BUN) had stabilized.
Drug formulation, dosage and administration.-Melphalan powder (Alkeran, Burroughs Wellcome Co., Research Triangle Park, NC) was stored in powder form at -4C until use. Immediately before administration, 1 ml of Burroughs Wellcome acid ethanol was added to 100 mg melphalan, which after dissolution was further diluted with 9 ml of Burroughs Wellcome brand diluent (i.e., K2HPO4 in propylene glycol and water) and placed on ice.
Blood and urine sampling.-Blood samples (10 ml) were collected in tubes containing 100 iu of heparin. Blood samples were taken just before the start of therapy and at 5, 15, 30, 45 and 60 min, and 2, 3, 4, 6, 8 and 24 h after drug injection. They were placed on ice for a short period before refrigerated centrifugation at 2000 rev/min for 10 min. The separated plasma samples were then stored at -20°C. Fractional urine collection, using size-8 straight, disposable catheters, were taken for the first 6 h after drug injection. The dogs were then placed in metabolic cages and urine was collected for 24h periods up to 3 days. The urine was drained from the bottom of the cage into collection bottles. The urinary volume of each 24h period was measured and aliquots were stored at -20°C in sterile containers to which concentrated HCI had been added as a preservative.
Blood counts and serum chemistries.-Standard procedures were used to measure renal function and complete blood counts on the dogs at weekly intervals to evaluate renal status and melphalan's haemopoietic toxicity.
Melphalan assays.-Melphalan was assayed in biological fluids using high-pressure liquid chromatography (HPLC) as previously described by Chang et al. (1978) .
Data analysis.-The concentrations of melphalan in plasma were averaged to obtain the combined data for the pre-and postnephrectomy groups, respectively. Each dog's data and the combined data for each group were then fitted to a multiexponential equation using a nonlinear-regression computer program, NONLIN (Metzler, 1969) . The half-lives and area under the plasma decay curve (C x T) were calculated from the parameters generated by curve fitting (Alberts et al., 1979a) . The melphalan renal clearances (Qr) were calculated from: Q = total urinary excretion Qr= CxT for each dog and then averaged for both preand post-nephrectomy groups.
To compare the effect of nephrectomy on melphalan pharmacokinetics, a two-tailed, unpaired Student's t test was used to compute the P values for the important parameters. A P of < 0 05 was taken as statistically significant.
RESULTS

Renal status
The BUN, serum creatinine and 24h urinary creatinine clearance before nephrectomy for 8 dogs averaged 19 9 + 5-3 mg/100 ml, 1 0+0 02 mg/100 ml, and 41-2 + 2-7 ml/min, respectively (Table I) . After surgical induction of renal failure, BUN increased more than 2-fold, serum creatinine more than 3-fold, and 24h urinary creatinine clearance decreased to less than half (Table I) . For each laboratory test pre-and post-nephrectomy values were statistically different, as shown in Table I . Melphalan-induced myelosuppression In the dogs with normal renal function, melphalan (1 mg/kg i.v.) produced the 4-9+07 115-0+23-0 0 9+0-2 9-7+3-0 0 001 0-002 before the pre-nephrectomy drug-induced nadirs).
PHARMACOKINETIC PARAMETERS
Melphalan plasma kinetics Prior to the surgical induction of renal dysfunction, the normal dogs had a melphalan ti4 of 435 + 31 min and an average C x T of 51b8 .t-g. min/ml (Table   III) plasma t./3 was 76-2 + 12-9 min and average C x T, 81 jug. min/ml. Melphalan's plasma tI, was significantly prolonged (P= 0-017) when computed from only terminal-slope data. Fig. 1 (Table  III) .
DISCUSSION
We have used a well-standardized dog model (Gierke et al., 1978) We do not recommend a dose reduction of orally administered melphalan in myeloma patients with diminished renal function. WJe have previously shown that there is marked variability of systemic availability of melphalan after oral administration (Alberts et al., 1979b) , and the oral route would tend to minimize the adverse marrow effects. When the parenteral route is used, however, the suggested dose a(djustments should be made.
